Recently, MedPHA Biotechnology Co., Ltd. ("MedPHA") successfully completed its Series B financing round. This round, with participation from Taiping Innovation and Guangyao Capital, represents a strong validation of MedPHA's technological capabilities and market potential, injecting significant momentum for the company to continue leading innovation in the PHA industry. The funds raised will be primarily utilized for the ongoing R&D and production of upstream and downstream PHA (polyhydroxyalkanoates) product lines, global market expansion, and the upgrading and development of the core team. Significantly, this financing arrives at a pivotal moment as the national "15th Five-Year Plan" explicitly designates new materials as one of four strategic emerging industries and biomanufacturing as one of six future industries, outlining a clear development direction. This strategic move, capitalizing on favorable conditions, underscores MedPHA's position as an industry benchmark and is of great significance.

As a leader in the field of bio-based degradable materials, MedPHA is dedicated to the research, development, production, and commercialization of the latest generation of fully bio-based, universally degradable PHA materials and their high-value health-related small molecules. The company actively explores their innovative applications in cutting-edge fields such as green health, medical health, and nutritional health, striving to become a global leader in these domains.

Leveraging its proprietary strain construction technology and intelligent biomanufacturing platform with independent intellectual property rights, MedPHA has successfully established a closed-loop industrial chain encompassing upstream strain engineering, midstream biomanufacturing, and downstream product application. This integrated approach has advanced the technological upgrade of the PHA biosynthesis industry, enabling MedPHA to pioneer open, continuous fermentation production and achieve large-scale manufacturing of PHA, demonstrating the speed and strength of Chinese biomanufacturing.

MedPHA's unique PHA novel biomaterial stands as a "new paradigm of green materials." It not only exhibits excellent thermoplastic processability and mechanical properties but also possesses multiple outstanding characteristics, including biodegradability, biocompatibility, high barrier properties, and piezoelectricity. Its application scenarios comprehensively cover numerous emerging fields such as food packaging, beverage and dairy packaging, electronics packaging, toys, 3D printing, paper coatings, drug delivery carriers, absorbable medical devices, and new food ingredients/additives. With its green credentials and multifunctional advantages, PHA is redefining the future boundaries of material applications, holistically empowering green industrial upgrading and contributing to the "Healthy China" initiative.

Ms. Lyu Jinyan, Co-founder and CEO of MedPHA, stated: "At this historic moment when the world collectively addresses the challenges of climate change, plastic pollution, and carbon emissions, MedPHA embraces its mission. Driven by green biomanufacturing, we are committed not only to solving critical bottleneck problems in the biomaterials sector but also, through high-standard strategic positioning, to reshaping the ecosystem of the biodegradable materials industry and leading the low-carbon circular economy. Looking towards the '15th Five-Year Plan' period, new materials and biomanufacturing have been elevated to the national strategic level. The PHA industry perfectly aligns with the essence of 'New Quality Productive Forces'—driving industrial upgrading through technological innovation to achieve high efficiency, high quality, and green, sustainable development. We firmly believe that PHA will become a key force in China's green and low-carbon transformation during the '15th Five-Year Plan' era, contributing Chinese wisdom to global sustainable development."

She added, "This financing round marks a significant milestone in the company's development. We sincerely appreciate the strong recognition and generous support from Taiping Innovation and Guangyao Capital! MedPHA will remain true to its original aspirations, continue to innovate vigorously, pursue high-quality development, and provide leading products and solutions for a green and low-carbon planet, for solving critical bottleneck and import substitution challenges in China's key biomedical materials sector, and for the 'Healthy China' strategy (particularly concerning brain health)."

A representative from Taiping Innovation commented: "As a bioengineering technology leading the future, synthetic biology deeply aligns with the national 'Dual Carbon' strategic direction. PHA materials hold immense development potential and strategic value in sectors like medical health, nutritional health, and green manufacturing. Leveraging the high-quality industrial ecosystem of the Hengqin Guangdong-Macao Cooperation Traditional Chinese Medicine Technology Industrial Park, operated by China Taiping Insurance Group, MedPHA has consistently achieved breakthroughs on the path to industrialization. Looking ahead, Taiping Innovation will accompany the company's growth, fostering the sustained and high-quality development of the domestic green biomanufacturing industry."

A representative from Guangyao Capital remarked: "Based on our in-depth analysis of synthetic biology technological innovation and the global carbon neutrality strategy, Guangyao Capital recognizes the core advantages and long-term value of MedPHA in the field of bio-based degradable materials. As a pioneer in continuous fermentation technology for PHA in China, MedPHA's open fermentation process not only overcomes the energy consumption bottlenecks of traditional processes but also secures a first-mover position in the global PHA market with its kiloton-scale production capacity and cost competitiveness. Its medical-grade PHA addresses high-end medical applications such as drug delivery carriers and absorbable sutures, directly tackling the shortcomings of traditional petroleum-based materials regarding non-degradability or stringent degradation conditions. Furthermore, MedPHA's consumer product line centered on beta-hydroxybutyric acid (BHB) precursors further broadens application boundaries, creating a comprehensive 'industrial-medical-consumer' coverage."

About Taiping Innovation

Taiping Innovation is one of the first insurance-sponsored private equity fund management companies established in China with approval from the former China Banking and Insurance Regulatory Commission. As the dedicated private equity investment platform under China Taiping Insurance Group, it leverages the professional advantages of insurance capital and the responsibility of a central enterprise. The funds it manages primarily focus on investment sectors such as healthcare, technological innovation, and rural revitalization.

About Guangyao Capital

Guangyao Capital is a private equity fund management company under Guangyao Group, specializing in investments within the biomedicine field and committed to advancing the development of the pharmaceutical and health industry.

Keywords: PHA biodegradable materials, PHA medical materials, Beta-hydroxybutyric acid (BHB) precursor health-active small molecules, MedPHA.